Wild-type IDH2 protects nuclear DNA from oxidative damage and is a potential therapeutic target in colorectal cancer
- 4 August 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Oncogene
- Vol. 40 (39), 5880-5892
- https://doi.org/10.1038/s41388-021-01968-2
Abstract
Although the role of isocitrate dehydrogenase (IDH) mutation in promoting cancer development has been well-characterized, the impact of wild-type IDH on cancer cells remains unclear. Here we show that the wild-type isocitrate dehydrogenase 2 (IDH2) is highly expressed in colorectal cancer (CRC) cells, and plays an unexpected role in protecting the cancer cells from oxidative damage. Genetic abrogation of IDH2 in CRC cells leads to reactive oxygen species (ROS)-mediated DNA damage and an accumulation of 8-oxoguanine with DNA strand breaks, which activates DNA damage response (DDR) with elevated γH2AX and phosphorylation of ataxia telangiectasia-mutated (ATM) protein, leading to a partial cell cycle arrest and eventually cell senescence. Mechanistically, the suppression of IDH2 results in a reduction of the tricarboxylic acid (TCA) cycle activity due to a decrease in the conversion of isocitrate to α-ketoglutarate (α-KG) with a concurrent decrease in NADPH production, leading to ROS accumulation and oxidative DNA damage. Importantly, abrogation of IDH2 inhibits CRC cell growth in vitro and in vivo, and renders CRC cells more vulnerable to DNA-damaging drugs. Screening of an FDA-approved drug library has identified oxaliplatin as a compound highly effective against CRC cells when IDH2 was suppressed. Our study has uncovered an important role of the wild-type IDH2 in protecting DNA from oxidative damage, and provides a novel biochemical basis for developing metabolic intervention strategy for cancer treatment.Funding Information
- National Key R&D Program of China
- National Natural Science Foundation of China
This publication has 46 references indexed in Scilit:
- Altered expression levels of IDH2 are involved in the development of colon cancerExperimental and Therapeutic Medicine, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Mutant Metabolic Enzymes Are at the Origin of GliomasCancer Research, 2009
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarateNature, 2009
- IDH1andIDH2Mutations in GliomasThe New England Journal of Medicine, 2009
- Mitochondria, oxidative stress and cell deathApoptosis, 2007
- The Consensus Coding Sequences of Human Breast and Colorectal CancersScience, 2006
- Molecular mechanism of ‘mitocan’‐induced apoptosis in cancer cells epitomizes the multiple roles of reactive oxygen species and Bcl‐2 family proteinsFEBS Letters, 2006
- Mitochondrial respiratory chain inhibitors induce apoptosisFEBS Letters, 1994
- Isocitrate dehydrogenase and related oxidative decarboxylasesFEBS Letters, 1980